Literature DB >> 6137387

Captopril combined with minoxidil, beta-blocker and furosemide in the treatment of refractory hypertension.

Y K Seedat, R Rawat.   

Abstract

14 patients with refractory hypertension did not respond either to captopril, an angiotensin II converting enzyme inhibitor, combined with a diuretic, a beta-blocker and hydralazine or minoxidil, a potent vasodilator, but they did respond to the combination of captopril, minoxidil, furosemide and a beta-blocker. There were no disturbing side effects from this combination. There may be a synergistic effect between captopril and minoxidil in the treatment of refractory hypertension. The combination is an interesting and novel method of treating patients with refractory hypertension.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6137387     DOI: 10.1007/bf00544006

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  2 in total

1.  Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study.

Authors: 
Journal:  JAMA       Date:  1977-01-17       Impact factor: 56.272

2.  Minoxidil in combination with a beta-adrenergic blocker and a diuretic as an antihypertensive in patients refractory to available medications.

Authors:  Y K Seedat; R Rawat
Journal:  S Afr Med J       Date:  1981-05-09
  2 in total
  3 in total

Review 1.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

2.  [Results of a 5-year study with captopril in patients with severe therapy-resistant hypertension].

Authors:  J Schrader; G Schoel; F Scheler
Journal:  Klin Wochenschr       Date:  1986-08-01

Review 3.  Perspectives on research in hypertension.

Authors:  Y K Seedat
Journal:  Cardiovasc J Afr       Date:  2009 Jan-Feb       Impact factor: 1.167

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.